Key highlights
- 1The single-use bioprocessing assemblies market is expected to reach USD 19 billion by 2036, at a CAGR of 14.0% from 2026 to 2036, driven by biologics growth, flexible manufacturing, and contamination control.
- 2Assemblies integrate the fluid path. Single-use assemblies combine bioprocess bags, tubing, connectors, clamps, filters and sensors into application-specific configurations for sterile fluid handling, storage and transfer.
- 3Flexible, closed manufacturing is the driver. Adoption reflects the shift to flexible, closed and scalable bioprocessing, reducing cross-contamination risk, cleaning requirements, water consumption and facility turnaround times.
- 4Biologics and advanced therapies expand demand. Rising biopharmaceutical research and manufacturing, expanding vaccine capacity, and growing cell and gene therapy production drive demand for single-use assemblies.
- 5Standardization is unlocking growth. Standards for extractables and leachables, such as USP 665, and closed-processing requirements are supporting adoption and standardization of single-use systems.
- 6Continuous and intensified processing. Growing use of continuous and integrated bioprocessing workflows increases the use of connected single-use assemblies across the process.
- 7Key companies include Sartorius AG, Cytiva (Danaher), Thermo Fisher Scientific, Merck KGaA (MilliporeSigma), and Saint-Gobain Life Sciences.
Report Overview
The single-use bioprocessing assemblies market covers pre-assembled, disposable fluid-path assemblies for biopharmaceutical manufacturing, spanning bag, tubing, filtration, connector and sampling and sensor assemblies, across upstream, downstream and fill-finish applications, for biopharmaceutical companies, contract manufacturers and research. Standalone components not sold as assemblies, stainless-steel systems, and non-biopharmaceutical uses are outside the scope except as context. Single-use assemblies are the integrated fluid-path products at the heart of flexible biomanufacturing. Demand is shaped by biologics and advanced therapy growth, closed and continuous processing, contamination control, and standardization. This report examines the size, drivers, product types, applications, end users, pricing, regions, competition, recent developments, and outlook of the market, and provides recommendations. Sizing is built bottom-up from assembly types by application, end user and region, and reflects single-use assemblies used in biomanufacturing.
Market dynamics
Drivers
- 01Biologics and advanced therapy growth is the primary driver as rising manufacturing of monoclonal antibodies, vaccines, GLP-1 medicines and cell and gene therapies increases demand for single-use assemblies, which suit the flexible, multi-product manufacturing these therapies require.
- 02Flexible and closed manufacturing is a strong driver as the shift from stainless-steel to single-use reduces cleaning, validation, water use and turnaround, and closed single-use assemblies enable flexible, scalable facilities.
- 03Contamination control is a driver as single-use assemblies are pre-sterilized and closed, reducing cross-contamination risk in multi-product operations.
- 04Standardization is a driver as extractables and leachables standards such as USP 665 and closed-processing requirements support adoption and platform standardization.
Opportunities
- 01Cell and gene therapy assemblies are a leading opportunity as advanced therapies use single-use, closed, often smaller-scale assemblies for flexible, contamination-controlled manufacturing.
- 02Continuous and intensified processing is an opportunity as connected single-use assemblies enable continuous workflows across the process.
- 03Standardized platform assemblies are an opportunity as standardization reduces validation and lead time and supports supply.
- 04Supply security is an opportunity as biopharma companies seek dual-sourcing and resilient supply of single-use assemblies after past constraints.
Trends
- 01The shift to closed and single-use processing is the defining trend as biomanufacturing moves from stainless-steel to flexible single-use systems.
- 02Standardization is a trend with extractables and leachables standards such as USP 665 and platform assemblies reducing validation burden.
- 03Integrated pre-assembled solutions are a trend as suppliers deliver complete, application-specific assemblies rather than components, simplifying customer operations.
- 04Supply resilience is a trend as biopharma companies and suppliers build dual-sourcing and capacity after supply constraints during the vaccine surge.
Report Summary
| Base Year | 2025 |
|---|---|
| Forecast Period | 2026-2036 |
| Market Size (2025) | USD 4.5 billion |
| Market Size (2026) | USD 5.1 billion |
| Market Size (2036) | USD 19 billion |
| CAGR (Value) | 14.0% (2026-2036) |
| Format | PDF & Excel |
| Segments Covered | By Product: Bag Assemblies, Tubing Assemblies, Filtration Assemblies, Connector Assemblies, Sampling & Sensor Assemblies. By Application: Upstream, Downstream, Fill-Finish. By End User; By Region. |
| Geographies Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
| Key Companies | Sartorius AG, Cytiva (Danaher), Thermo Fisher Scientific, Merck KGaA (MilliporeSigma), Saint-Gobain Life Sciences, Colder Products Company (Dover), Watson-Marlow Fluid Technology Solutions, Avantor, Inc., Entegris, Foxx Life Sciences, Other Companies |
Segmental analysis
By Product
- Bag assemblies hold the largest share at about 35% of the market in 2026, with the remaining share divided across tubing, filtration, connector, and sampling and sensor assemblies.
- Bag assemblies including two-dimensional and three-dimensional bioprocess bags integrated with tubing and connectors for mixing, storage and bioreactors, are the largest product because they are central to upstream and storage operations and carry significant value.
- Tubing assemblies integrating tubing with connectors and clamps for fluid transfer, are a large product across the process.
- Filtration assemblies integrate filters into the fluid path for clarification and sterile filtration.
- Connector assemblies provide sterile fluid-transfer connections and sampling and sensor assemblies enable in-process sampling and monitoring.
The dominance of bag assemblies reflects their central role and value in single-use processing.
By Application
- Upstream holds the largest share at about 45% of the market in 2026, with the remaining share divided across downstream and fill-finish.
- Upstream including media and buffer preparation, cell culture and bioreactor operations, is the largest application because it uses large single-use bags, bioreactors and fluid-transfer assemblies and is where single-use adoption is deepest.
- Downstream including purification, filtration and chromatography, uses filtration and fluid-transfer assemblies.
- Fill-finish and final filling use single-use assemblies for sterile transfer to filling.
The dominance of upstream reflects the scale and single-use intensity of media handling and cell culture, while downstream and fill-finish grow with single-use adoption.
By End User
- Biopharmaceutical companies hold the largest share at about 55% of the market in 2026, with the remaining share divided across contract manufacturers and academic and research institutes.
- Biopharmaceutical companies are the largest end user because they manufacture biologics and advanced therapies at scale and are the primary adopters of single-use assemblies.
- Contract development and manufacturing organizations are a large and growing end user, as they rely on flexible single-use manufacturing to serve multiple clients.
- Academic and research institutes use single-use assemblies in process development and research.
The dominance of biopharmaceutical companies reflects the scale of commercial manufacturing, while contract manufacturers grow with outsourcing.
Geographic analysis
North America Single-Use Bioprocessing Assemblies Market
North America is the largest regional market driven by its large biopharmaceutical industry, strong biologics and advanced therapy manufacturing, and leading single-use suppliers and contract manufacturers. The region leads in single-use adoption and hosts major suppliers and biomanufacturers. Strong biopharma manufacturing and single-use adoption make North America the leading market for single-use assemblies.
Europe Single-Use Bioprocessing Assemblies Market
Europe is a major market home to leading single-use suppliers including Sartorius, Merck KGaA and Sartorius's and others' manufacturing, and significant biomanufacturing. European biopharma companies and contract manufacturers are deep adopters of single-use systems, and the region has strong regulatory and quality standards. Europe is a leading and growing market with strong supply and adoption.
Asia-Pacific and Rest of World
Asia-Pacific is a large and fast-growing market with expanding biopharmaceutical manufacturing in China, India, South Korea and elsewhere, growing contract manufacturing, and rising single-use adoption. The rest of the world adds growing demand as biomanufacturing spreads. These regions add strong growth as biopharmaceutical capacity is built and single-use adoption deepens.
Pricing Analysis
Pricing in single-use assemblies reflects configuration, customization, and validation. Assemblies are priced per configuration, with complex, custom, multi-component assemblies costing more than simple ones, and the value reflecting integration, sterility, quality documentation and supply. Assemblies are recurring consumables, used per batch, and their cost is weighed against the cleaning, validation, water and capital savings of single-use versus stainless-steel. Several factors set price. Configuration and complexity are central, as multi-component, custom assemblies cost more than standard ones. Customization affects price, as bespoke assemblies carry design and validation cost, while standardized platforms lower it. Validation and documentation, including extractables and leachables data, add cost and value. Materials and supply affect price, as polymer film, tubing and connectors and their supply drive cost. Volume and standardization lower unit cost.
The trajectory of pricing depends on standardization, materials and supply, and volume, and standardization and scale moderate cost even as complex assemblies command a premium, with single-use economics favourable against stainless-steel for flexible, multi-product manufacturing.
Competitive landscape
The market is led by large bioprocessing suppliers and includes connector and specialty companies. Sartorius, Cytiva, part of Danaher, Thermo Fisher and Merck KGaA, through MilliporeSigma, are the major bioprocessing suppliers offering complete single-use assembly portfolios of bags, tubing, filters, connectors and sensors. Saint-Gobain Life Sciences supplies tubing, films and assemblies, and Colder Products Company, part of Dover, and Watson-Marlow provide connectors and fluid-transfer components and assemblies. Avantor, Entegris and Foxx Life Sciences supply single-use components and assemblies, and other specialists serve the market.
Competition turns on portfolio breadth and integration, quality and validation support, supply reliability and capacity, and standardization, and the market is led by large bioprocessing suppliers with broad single-use portfolios alongside connector and specialty companies. Biologics growth, closed processing and standardization favour suppliers with complete, validated, reliably supplied assembly portfolios, and Sartorius, Cytiva, Thermo Fisher and Merck hold strong positions, with connector and specialty companies important in the fluid path. The field is consolidating around integrated suppliers while specialists provide key components, and supply reliability and standardization are increasingly decisive.
Voice of Customer
Single-use assemblies let us run flexible, multi-product manufacturing without the cleaning and validation burden of stainless-steel, and closed assemblies reduce our cross-contamination risk. We value complete, pre-assembled, validated assemblies with extractables and leachables data, and after past supply constraints we prioritise suppliers with reliable capacity and dual-sourcing.
Manufacturing director, biopharmaceutical company (North America):
As a CDMO we rely on single-use to switch quickly between client products, and integrated assemblies simplify our operations. We look at portfolio breadth, quality documentation and supply reliability, and standardization across bags, tubing and connectors reduces our validation work and lead times.
Process engineer, contract manufacturer (Europe):
Our advanced therapy needs closed, single-use, often smaller-scale assemblies with rigorous sterility, and we work with suppliers who can provide custom, validated fluid paths. Reliability and quality matter most, and connected assemblies with sampling and sensors help us monitor our sensitive processes.
Head of process development, cell therapy company (North America):
Analyst perspective
The single-use bioprocessing assemblies market is a steadily growing market at the heart of the biomanufacturing shift to flexible, closed and single-use processing. Single-use assemblies integrate bags, tubing, connectors, filters and sensors into pre-assembled, sterile fluid paths, and their adoption reflects the industry's move from stainless-steel to flexible manufacturing that reduces cleaning, validation, water use and turnaround. Biologics, vaccines, GLP-1 medicines and cell and gene therapies are driving demand, standardization such as extractables and leachables requirements is supporting adoption, and continuous and intensified processing is increasing the use of connected assemblies. Large bioprocessing suppliers with broad portfolios lead, alongside connector and specialty companies.
The honest considerations are supply and materials, sustainability, and validation. The market experienced supply constraints during the vaccine surge, and supply reliability, capacity and dual-sourcing remain priorities, with polymer film, tubing and connector supply a consideration. Single-use generates plastic waste, and sustainability and waste management are growing concerns that the industry must address, even as single-use saves water and energy versus stainless-steel cleaning. Validation, change control and extractables and leachables requirements add complexity, though standardization is reducing the burden. The economics favour single-use for flexible, multi-product and smaller-scale manufacturing, but very large-scale production can still favour stainless-steel. The market should be assessed on biomanufacturing growth, single-use adoption depth, and supply and standardization rather than on the flexibility theme alone, and biologics growth and single-use adoption support steady growth, with supply, sustainability and validation the key variables.
Key Strategic Developments
- 2024-2026: Biopharmaceutical companies and contract manufacturers deepened adoption of single-use assemblies for flexible, closed manufacturing of biologics, vaccines and advanced therapies.
- 2024-2026: Standards for extractables and leachables, such as USP 665, advanced, supporting standardization and adoption of single-use systems and reducing validation burden.
- 2024-2026: Suppliers expanded integrated, pre-assembled single-use offerings and manufacturing capacity, and pursued supply resilience and dual-sourcing after past constraints.
- 2024-2026: Growing use of continuous and intensified bioprocessing increased demand for connected single-use assemblies with sampling and sensor integration.
- 2024-2026: Cell and gene therapy manufacturing expanded, driving demand for closed, often smaller-scale, custom single-use assemblies.
Strategic Recommendations
For single-use suppliers
The priority is to provide complete, validated, reliably supplied assembly portfolios and to advance standardization and supply resilience, because the market rewards integrated, dependable single-use systems and was constrained by past supply issues. Companies should offer integrated assemblies across bags, tubing, filters, connectors and sensors, provide extractables and leachables data and standardized platforms, build capacity and dual-sourcing, and support cell and gene therapy and continuous processing. Addressing sustainability and waste strengthens the position.
For biopharma companies and contract manufacturers
The recommendation is to adopt single-use assemblies for flexible, closed manufacturing where the economics favour it, prioritising validated, reliably supplied, standardized assemblies and dual-sourcing, and to weigh single-use against stainless-steel by scale. For suppliers and users alike, addressing single-use plastic waste is increasingly important. For investors, this is a steadily growing market tied to biomanufacturing, to evaluate on biomanufacturing growth, single-use adoption depth, and supply and standardization rather than on the flexibility theme alone, recognising that biologics growth and single-use adoption support steady growth while supply, sustainability and validation are the key variables.
Sustainability impact
Water and Energy Savings versus Stainless-Steel
Single-use assemblies eliminate the cleaning and sterilization of stainless-steel systems, saving water and energy. Single-use assemblies support resource savings.
By removing the need to clean and sterilize stainless-steel equipment between batches, single-use assemblies reduce the water, energy and chemicals used in biomanufacturing, an important resource saving that partly offsets the impact of disposable materials.
Contamination Control and Product Safety
Closed, pre-sterilized single-use assemblies reduce contamination risk, protecting product quality and patient safety. Single-use assemblies support product safety.
By providing closed, pre-sterilized fluid paths, single-use assemblies reduce cross-contamination risk in multi-product manufacturing, protecting the quality and safety of biologic medicines, an important health contribution.
Plastic Waste and Circularity
Single-use assemblies generate plastic waste, so recycling and circular approaches are important to their sustainability.Single-use assemblies require waste management.
By relying on disposable plastic components, single-use assemblies generate waste, so recycling programs, waste-to-energy and emerging circular approaches for single-use plastics are important to managing their environmental impact.
Supply Resilience and Access
Reliable supply of single-use assemblies supports resilient biomanufacturing and access to medicines. Single-use assemblies support supply resilience.
By underpinning flexible biomanufacturing, reliable single-use assembly supply supports resilient production of vaccines and biologics and access to medicines, so supply security and dual-sourcing are part of the sustainability of the biomanufacturing system.
Table of contents
14 chapters · 100 pages · click to expandFrequently asked questions
The single-use bioprocessing assemblies market was valued at USD 4.5 billion in 2025 and is projected to reach USD 19 billion by 2036, growing from USD 5.1 billion in 2026, at a CAGR of 14.0% from 2026 to 2036, driven by biologics growth, flexible manufacturing, and contamination control.